Testing new markers in chest fluid from lung adenocarcinoma patients
Checks new molecular markers in chest fluid to help detect lung cancer.
Key facts
- Who runs it
- Fu Jen Catholic University
- Where
- New Taipei City, TaiwanSee the site
- Trial code
- Registry title
- Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 10 Jun 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- biomarkers
- Record updated
- 5 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who need a physician-ordered procedure to drain fluid from around the lung (pleural effusion). It tests new markers in that fluid for lung adenocarcinoma.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- People with fluid around the lung (pleural effusion) who need it drained.
Main reasons for not taking part
- Under 18 years old
- Cancer other than lung adenocarcinoma
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need
- Signed informed consent
Who cannot take part
- Patients with malignancies other than lung adenocarcinoma
- Patients under the age of 18
Where in Taiwan
- Fu Jen Catholic University Hospital, Fu Jen Catholic UniversityNew Taipei City, TaiwanContact: Ke-Yun Chao, PhDTaking people
About the trial
What the trial wants to find out
This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.
The 2 groups in the trial
- Case group
Patients with pleural effusion diagnosed as lung adenocarcinoma.
Treatment: biomarkers
- Control group
Patients with pleural effusion diagnosed as non-malignant.
Treatment: biomarkers
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Novel Pleural Effusion Biomarkers Screening and Evaluation in Lung Adenocarcinoma Patients
- Plain-language title
- Testing new markers in chest fluid from lung adenocarcinoma patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 5 March 2026